Uğur BERBEROĞLU, Kaptan GÜLBEN, Orhan ÇELEN, Hüseyin ALTINYOLLAR

Meme kanserinin infraklavikular metastazlarının prognostik parametreler ile korelasyonu

Meme kanserli olgularda infraklavikular metastaz bulunması AJCC (American Joint Committee on Cancer) evrelemesine göre evre III C olarak değerlendirilmekte ve lokal ileri hastalık kabul edilmektedir. Meme kanserinde infraklavikular metastazın prognostik önemi araştırıldı. Gereç-Yöntem: Ankara Onkoloji Hastanesinde cerrahi tedavi uygulanan 890 meme kanseri olgusunun 428’ inde aksiller metastaz vardı (% 48). Aksiller metastazlı olgular, infraklavikular lenf nodu metastazı bulunan ve bulunmayan olmak üzere iki gruba ayrıldı. İki grup arasında klinik ve patolojik parametreler ile lokal nüks ve sistemik metastaz yönünden araştırıldı. Bulgular: Level I ve II’ de aksiller metastaz bulunan 428 olgunun 183’ ünde infraklavikular (level III) metastaz da vardı (% 42.8). İnfraklavikular metastaz bulunan grupta; genç yaş, premenapozal, tümör çapı büyük, gradı yüksek, lenfatik ve damar invazyonu bulunan, aksillada metastatik lenf nodu 4’ den çok olan, ekstranodal invazyon bulunan olgular anlamlı olarak daha fazla idi (p

Correlation of infraclavicular metastasis in breast cancer with prognostic parameters

Breast cancer patients with infraclavicular metastasis are considered to have stage IIIC and locally advanced disease according to the American Joint Committee on Cancer (AJCC) TNM classification. The prognostic significance of infraclavicular metastasis in breast cancer patients was evaluated. Patients and Method: Among 890 surgically treated breast cancer patients, 428 (48%) had axillary metastasis. These patients with axillary metastasis were divided into two groups: patients with and without infraclavicular lymph node metastasis. The clinicopathologic factors of these two groups were evaluated with respect to local recurrence and systemic metastasis. Results: Among the 428 patients with level I and II axillary metastasis, 183 (42.8%) had infraclavicular metastasis. Patients with young age, premenopausal status, large tumor size, high-grade tumor, lymphatic and vascular invasion, extranodal invasion and axillary lymph node metastasis >4 were significantly higher in the infraclavicular metastasis group (p

PDF

___

1. Singletary SE, Allred C, Ashley et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
2. Kuru B, Camlibel M, Dinc S, et al. Prognostic significance of apex axillary invasion for locoregional recurrence and effect of postmastectomy radiotherapy on overall survival in node-positive breast cancer patients. World J Surg 2004; 28: 236-241.
3. Zurrida S, Morabito A, Galimberti V, et al. Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer. Int J Oncol 1999;15: 475-480.
4. Canavese G, Catturich A, Vecchio C, et al. Prognostic role of lymph node level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg kOncol 1998; 24: 104-109.
5. Barth RJ, Danforth DN, Venzon DJ, et al. Level of axillary involvement by lymph-node metastases from breast cancer is not an independent predictor of survival. Arch Surg 1991; 126: 574-577.
6. Haagensen CD. The natural history of breast carcinoma. Disease of the Breast, 3rd edn. Philadelphia, PA: WB Saunders, 1986: 663-664.
7. Veronesi U, Rilke F, Luini A, et al. Distribution of axillary node metastases by level of invasion. Cancer 1987; 59: 682-687.
8. Newman LA, Kuerer HM, Fornage B, Mirza N, Hunt KK, Ros MI et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001; 181: 313-318.
9. Morrow M. Axillary dissection: When and how radical. Semin Surg Oncol 1996; 12: 321-327.
10. Tominaga T, Takashima S, Danno M et al. Randomized clinical trial comparing level II and level III axillary node dissection in addition to mastectomy for breast cancer. Br J Surg 2004; 91: 38-43.
11. Sinha PS, Thrush S, Bendall S, et al. Does radical surgery to the axilla give a survival advantage in more severe breast cancer. Eur J Cancer 2002; 38: 1474-1477.
12. Sandjoy S, William BF, Donn CY, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 2000; 73: 134-137.
13. Ruffin WK, Stacey-Clear A, Youngen J, et al. Rationale for routine axillary dissection in carcinoma of breast. J Am Coll Surg 1995; 180: 245-251.
14. Black RB, Merrick MV, Taylor TV, et al. Prediction of axillary metastases in breast cancer by lymphoscintigraphy. Lancet 1980; 11: 15-17.
15. Goldenberg DM, Wegener W. Studies of breast cancer imaging with radiolabeled antibodies to carcinoembryonic antigen. Immunomedics Breast Cancer Study Group. Acta Med Austriaca 1997; 24: 55-59.
16. Fisher ER, Costantino J, Fisher B, et al. Collaborating National Breast and Bowel Project investigators. Pathologic findings from the National Surgucal Adjuvant Breast Project (Protocol 4): discriminants for 15-year survival. Cancer 1993; 71: 2141-2150.
17. Martin JK, van Herden JA, Taylor WF, et al. Is modified radical mastectomy really equivalent to radical mastectomy of carcinoma of the breast? Cancer 1986; 57: 510-518.
18. Fisher B, Slack N, Katrych D, et al. Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975; 140: 528-534.
19. Voss M, Schneider JW, Apffelstaedt J. Axillary lymph node involvement in stage III breast cancer: Treatment implication. J Surg Oncol 1999; 71: 162-166.
20. Senofsky GM, Moffat FL, Davis K, et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991; 126: 1336-4132.
21. Chua B, Ung O, Taylor R, et al. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 2002; 72: 786-792.
22. Gaglia P, Bussone R, Caldarola B, et al. The correlation between the spread of metastases by level in the axillary nodes and disease-free survival in breast cancer. A multifactorial analysis. Eur J Cancer Clin Oncol 1987; 23: 849-854.
23. Valli M, Lanza A, Giani R, et al. Surgical strategy management following lymph nodal positivity at the three levels (a retrospective and perspective study). Eur J Gynaecol Oncol 1987; 8: 585-589.
24. Recht A, Connolly JL, Schnitt SJ, et al. Conservative surgery and radiation therapy for early breast cancer: results, controversies, and unsolved problems. Sem Oncol 1986; 13: 434-449.